Alpha Teknova

Alpha Teknova, Inc. engages in the manufacture of cell culture media and supplements. It provides reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its product offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. The company was founded by Thomas E. Davis in 1996 and is headquartered in Hollister, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Teknova reports mixed Q1 results, focuses on expense management

Teknova's Q1 2023 earnings call showcased mixed financial results, with revenue growth in Lab Essentials but a decline in Clinical Solutions. The company remains focused on managing expenses and driving revenue growth while addressing customer concerns and advancing its R&D pipeline.

Teknova reports strong Q2 sales but revises 2023 revenue guidance

Teknova's Q2 performance reflects strong sales growth and effective expense management, but revised revenue guidance and financial challenges pose concerns. The company's strengths lie in its certified manufacturing facility, progressing R&D pipeline, and financial flexibility. However, challenges include a slowdown in clinical solutions revenue and financial strain. Despite this, Teknova sees opportunities in the long-term potential of its target markets and the positive reception of new product launches.

TKNO reports Q3 revenue decline but anticipates future growth

TKNO's Q3 performance saw capital raise and debt reduction, but revenue declined. The company faces challenges in revenue decline but sees opportunities for future growth and cash management.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HOLLISTER, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the first quarter ended March 31, 2024, on Monday, May 13, 2024, following the close of market.

Teknova to Report First Quarter 2024 Financial Results on May 13, 2024

The heavy selling pressure might have exhausted for Alpha Teknova (TKNO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down -28.04% in 4 Weeks, Here's Why Alpha Teknova (TKNO) Looks Ripe for a Turnaround

Alpha Teknova, Inc. (NASDAQ:TKNO ) Q4 2023 Earnings Conference Call March 11, 2024 5:30 PM ET Company Participants Jennifer Henry - Senior Vice President of Marketing Stephen Gunstream - President & Chief Executive Officer Matthew Lowell - Chief Financial Officer Conference Call Participants Mark Massaro - BTIG Jacob Johnson - Stephens Steven Mah - TD Cohen Madeline Mollman - William Blair Paul Knight - KeyBanc Operator Hello, and thank you for standing by. Welcome to Teknova Fourth Quarter 2023 Financial Results Conference Call.

Alpha Teknova, Inc. (TKNO) Q4 2023 Earnings Call Transcript

Full year 2023 total revenue was $36.7 million, down 11% year-over-year Achieved 36% annual growth in the number of Clinical Solutions customers in 2023 Company provides 2024 revenue guidance of $35-38 million

Teknova Reports Fourth Quarter and Full Year 2023 Financial Results

HOLLISTER, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2023, on Monday, March 11, 2024, following the close of market.

Teknova to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024

Alpha Teknova, Inc. (TKNO) Q3 2023 Earnings Call Transcript

Raised $22.9 million of equity capital, paid down $10.0 million of long-term debt Third quarter 2023 total revenue was $8.2 million, down 24% from prior year Expect 2023 revenue at the low end of previously announced guidance range of $37-40 million HOLLISTER, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the third quarter ended September 30, 2023.

Teknova Reports Third Quarter 2023 Financial Results

Teknova today announced that the Company will report its financial results for the third quarter on Thursday, November 9, 2023, following close of market.

Teknova to Report Third Quarter 2023 Financial Results on November 9, 2023

Novel AEX screening kit – now available for AAV6 – and an expansive suite of high-quality reagents designed to expedite plasmid production will help accelerate breakthroughs across multiple AAV constructs and workflows Novel AEX screening kit – now available for AAV6 – and an expansive suite of high-quality reagents designed to expedite plasmid production will help accelerate breakthroughs across multiple AAV constructs and workflows

Teknova Launches Latest Proprietary AAV-Tek™ Product and End-to-End Plasmid Workflow Solutions to Streamline Therapeutic Process Development

HOLLISTER, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced the closing of its previously announced registered direct offering for the issuance and sale of an aggregate of 1,086,485 of its shares of common stock at a purchase price of $1.85 per share and concurrent private placement of an aggregate of 11,299,993 of its shares of common stock, at the same purchase price of $1.85 per share. The registered direct offering and the private placement were priced based on the consolidated closing bid price under Nasdaq rules.

Teknova Announces Closing of $22.9 Million Concurrent Registered Direct Offering and Private Placement and Amends Credit Facility

Alpha Teknova, Inc. (NASDAQ:TKNO ) Q2 2023 Earnings Conference Call August 10, 2023 5:30 PM ET Company Participants Sara Michelmore - MacDougall Advisors Stephen Gunstream - President & Chief Executive Officer Matthew Lowell - Chief Financial Officer Conference Call Participants Steven Mah - TD Cowen Matt Larew - William. Blair Paul Knight - KeyBanc Mark Massaro - BTIG Jacob Johnson - Stephens Operator Good day, and welcome to Teknova's Second Quarter 2023 Financial Results Conference Call.

Alpha Teknova, Inc. (TKNO) Q2 2023 Earnings Call Transcript

Second quarter 2023 total revenue was $11.5 million, up 26% sequentially Received certification of new state-of-the-art facility for production of GMP-grade products Company revises 2023 revenue guidance to $37-40 million, continues to anticipate free cash outflows of $30 million for full year

Teknova Reports Second Quarter 2023 Financial Results

State-of-the-art facility in Hollister, California is designed to help bioprocessing and gene therapy companies scale from research to clinical production State-of-the-art facility in Hollister, California is designed to help bioprocessing and gene therapy companies scale from research to clinical production

Teknova Announces Opening of New GMP-Certified Facility, Increasing Manufacturing Capacity for Custom, High-Quality Life Sciences Reagents

HOLLISTER, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2023, on Thursday, August 10, 2023, following the close of market.

Teknova to Report Second Quarter 2023 Financial Results on August 10, 2023

First-of-its-kind screening kit now available for AAV8 – along with a suite of high-quality reagents to support the entire AAV workflow – helping gene therapy developers save months in process development First-of-its-kind screening kit now available for AAV8 – along with a suite of high-quality reagents to support the entire AAV workflow – helping gene therapy developers save months in process development

Teknova Expands Proprietary AAV-Tek™ Solutions Product Line to Deliver End-to-End Solutions for Gene Therapy Process Development

HOLLISTER, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will present and host individual and small group meetings at the following upcoming investor conference:

Teknova to Participate in Upcoming Investor Conference

Alpha Teknova, Inc. (NASDAQ:TKNO ) Q1 2023 Earnings Conference Call May 10, 2023 5:30 PM ET Company Participants Jennifer Henry - Senior Vice President of Marketing Stephen Gunstream - President & Chief Executive Officer Matthew Lowell - Chief Financial Officer Conference Call Participants Jacob Johnson - Stephens Madeline Mollman - William Blair Steven Mah - TD Cowen Operator Good day, and welcome to the Teknova First Quarter 2023 Financial Results Call. [Operator Instructions] Please be advised that today's conference is being recorded.

Alpha Teknova, Inc. (TKNO) Q1 2023 Earnings Call Transcript

First quarter 2023 total revenue was $9.1 million, up 16% sequentially Launch of proprietary AAV-Tek™  Solutions gene therapy product line Company reaffirms 2023 revenue guidance of $42-46 million HOLLISTER, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the first quarter ended March 31, 2023.

Teknova Reports First Quarter 2023 Financial Results

Company will share their latest findings for custom product innovations aimed at addressing key gene therapy bioprocessing bottlenecks Company will share their latest findings for custom product innovations aimed at addressing key gene therapy bioprocessing bottlenecks

Teknova to Present Data on Novel Products to Accelerate the Development of AAV Therapies at ASGCT 2023 Annual Meeting

Alpha Teknova (TKNO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Alpha Teknova (TKNO) a New Strong Buy Stock

HOLLISTER, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the first quarter ended March 31, 2023, on Wednesday, May 10, 2023, following the close of market.

Teknova to Report First Quarter 2023 Financial Results on May 10, 2023

Alpha Teknova (TKNO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Alpha Teknova (TKNO) Loses -29.93% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Down -48.43% in 4 Weeks, Here's Why You Should You Buy the Dip in Alpha Teknova (TKNO)

Alpha Teknova, Inc. (NASDAQ:TKNO ) Q4 2022 Results Conference Call March 15, 2023 5:00 PM ET Company Participants Jen Henry - Senior Vice President of Marketing Stephen Gunstream - President & Chief Executive Officer Matt Lowell - Chief Financial Officer Conference Call Participants Joseph Flanagan - Cowen Matt Larew - William Blair Hannah Hefley - Stephens Operator Thank you for standing by, and welcome to Teknova's Fourth Quarter and Full Year 2022 Financial Results Call. At this time, all participants are in a listen-only mode.

Alpha Teknova, Inc. (TKNO) Q4 2022 Earnings Call Transcript

Full year 2022 total revenue was $41.4 million, up 12% year-over-year New, state-of-the-art manufacturing facility now operational Company provides 2023 revenue guidance of $42-46 million

News for Alpha Teknova Stock (TKNO)